Grifols, S.A. (GRFS)
| Market Cap | 6.52B |
| Revenue (ttm) | 8.83B |
| Net Income (ttm) | 472.00M |
| Shares Out | 680.58M |
| EPS (ttm) | 0.69 |
| PE Ratio | 13.82 |
| Forward PE | 8.78 |
| Dividend | $0.14 (1.76%) |
| Ex-Dividend Date | Aug 12, 2025 |
| Volume | 1,568,609 |
| Open | 8.11 |
| Previous Close | 8.13 |
| Day's Range | 8.07 - 8.17 |
| 52-Week Range | 6.90 - 11.14 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 10.15 (+25.77%) |
| Earnings Date | Jul 28, 2022 |
About GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRFS stock is "Hold." The 12-month stock price target is $10.15, which is an increase of 25.77% from the latest price.
News
Manitoba medical examiner says investigations complete in deaths of plasma donors
The office of Manitoba's chief medical examiner says it completed an autopsy on one of the two people who died after donating plasma at Winnipeg locations run by Grifols, a private collection company ...
Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures
Grifols (GRFS) Faces Health Canada's New Regulations After Inspection Failures
Health Canada slaps new conditions on plasma donation company Grifols, still reviewing 2 Manitoba deaths
Health Canada has slapped new terms and conditions on all of a company's paid plasma centres after multiple failed inspections where the regulator found "recurring, systemic deficiencies."
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people wh...
Bullish Two Hundred Day Moving Average Cross - GRF
In trading on Wednesday, shares of Eagle Capital Growth Fund Inc (Symbol: GRF) crossed above their 200 day moving average of $10.48, changing hands as high as $10.74 per share. Eagle Capital Growth Fu...
Grifols approves IPO of its US biopharma business
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease
BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-conc...
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg af...
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites
WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid...
Grifols Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA grew strongly in 2025, with free cash flow and leverage targets exceeded. Strategic partnerships in Egypt and Canada, along with a focus on margin-accretive growth, position the company for continued deleveraging and profitability in 2026.
Grifols doubles net profit in 2025, driven by revenues
Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euro...
Grifols Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and EBITDA growth, led by immunoglobulins and biopharma, with improved free cash flow and leverage. Guidance for 2025 is reaffirmed, despite FX and IRA headwinds, and the pipeline remains robust with key launches on track.
Spanish court summons Gotham City founder in Grifols share price probe
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...
Grifols Earnings Call Transcript: Q2 2025
H1 2025 saw robust revenue and EBITDA growth, margin expansion, and strong Free Cash Flow, driven by Biopharma and Diagnostics. Leverage hit a five-year low, dividend payments resumed, and guidance for 2025 was reaffirmed despite FX and pricing pressures.
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and...
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF...
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...
Grifols says on course to meet 2025 outlook as net profit triples
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
Grifols Earnings Call Transcript: Q1 2025
Q1 2025 delivered record revenue, EBITDA, and free cash flow, with strong growth in biopharma and diagnostics. Guidance for 2025 is reaffirmed, supported by robust demand, operational efficiencies, and a resilient global supply chain, despite ongoing policy and macroeconomic uncertainties.
IBL International collaborates with Grifols on advanced biomarker panels
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...
Brookfield resumes Grifols takeover talks, El Confidencial reports
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial...
Grifols expects to boost revenue and free cash flow, shares soar
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...
Grifols Transcript: CMD 2025
Management outlined a five-year plan to reach €10 billion revenue by 2029 and €14 billion by 2034, driven by biopharma growth, innovation, and operational efficiency. Margin expansion, disciplined capital allocation, and new product launches underpin the strategy, with dividends to resume in 2025.
Grifols Earnings Call Transcript: Q4 2024
Record revenues and adjusted EBITDA were achieved in 2024, driven by strong Biopharma growth, robust demand for immunoglobulin and albumin, and operational efficiencies. Free cash flow and deleveraging exceeded expectations, with no major CapEx needed in the near term.
Grifols' sales rise over 10% in 2024, above target
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7%...